About Splice Bio
Splice Bio is a company based in Barcelona (Spain) founded in 2020.. Splice Bio has raised $191.7 million across 3 funding rounds from investors including Roche, EQT and Ysios Capital. Splice Bio offers products and services including Protein Splicing Platform and SB-007. Splice Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Barcelona, Spain
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Splicebio, S.L.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$191.7 M (USD)
in 3 rounds
-
Latest Funding Round
$135 M (USD), Series B
Jun 11, 2025
-
Investors
Roche
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Splice Bio
Splice Bio offers a comprehensive portfolio of products and services, including Protein Splicing Platform and SB-007. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for developing advanced gene therapies for genetic diseases.
Dual-AAV treatment targeting Stargardt disease through clinical trials.
Unlock access to complete
Unlock access to complete
Funding Insights of Splice Bio
Splice Bio has successfully raised a total of $191.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $135.0M
- First Round First Round
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Series B - Splice Bio | Valuation | EQT , Sanofi Ventures | |
| Feb, 2022 | Amount | Series A - Splice Bio | Valuation | Ysios Capital , UCB Ventures | |
| Sep, 2020 | Amount | Seed - Splice Bio | Valuation | Ysios Capital , Asabys Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Splice Bio
Splice Bio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, EQT and Ysios Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ysios Capital is recognized as a leading life sciences investor.
|
Founded Year | Domain | Location | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Splice Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Splice Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Splice Bio Comparisons
Competitors of Splice Bio
Splice Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Splice Bio
Frequently Asked Questions about Splice Bio
When was Splice Bio founded?
Splice Bio was founded in 2020.
Where is Splice Bio located?
Splice Bio is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Is Splice Bio a funded company?
Splice Bio is a funded company, having raised a total of $191.7M across 3 funding rounds to date.
What does Splice Bio do?
Splice Bio was founded in 2020 in Barcelona, Spain, within the biotechnology sector. A proprietary intein platform technology is provided to address rare genetic diseases through gene therapy. Operations center on developing treatments, with the lead program targeting Stargardt disease, an inherited retinal disorder linked to ABCA4 gene mutations. The platform enables precise genetic interventions for affected patients.
Who are the top competitors of Splice Bio?
Splice Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Splice Bio offer?
Splice Bio offers Protein Splicing Platform and SB-007.
Who are Splice Bio's investors?
Splice Bio has 10 investors. Key investors include Roche, EQT, Ysios Capital, UCB Ventures, and NEA.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.